

# CITATION REPORT

List of articles citing

**Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial**

**DOI: 10.1038/sj.bjc.6603351**

**British Journal of Cancer, 2006, 95, 788-93.**

**Source:** <https://exaly.com/paper-pdf/41276215/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
51	NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemotherapy and radiotherapy. <i>British Journal of Cancer</i> , <b>2007</b> , 97, 105-11	8.7	53
50	A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. <i>Annals of Oncology</i> , <b>2007</b> , 18, 1152-8	10.3	45
49	HER2-positive breast cancer: current and future treatment strategies. <i>Drugs</i> , <b>2007</b> , 67, 1329-41	12.1	91
48	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. <i>BMC Cancer</i> , <b>2008</b> , 8, 209	4.8	8
47	European oncologists' preferences for the management of breast cancer: case presentations and expert commentary. <i>Breast</i> , <b>2008</b> , 17 Suppl 2, S1-S12	3.6	2
46	A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2008</b> , 8, 264-8	3	20
45	Anticorps anti-HER2. <b>2008</b> , 11-33		
44	HER-2-positive metastatic breast cancer: trastuzumab and beyond. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 2583-601	4	35
43	Vinorelbine in breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 2901-10	4	9
42	A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer. <i>Clinical Medicine Therapeutics</i> , <b>2009</b> , 1, CMT.S35		
41	A Review of Vinorelbine in the Treatment of Advanced Breast Cancer. <i>Clinical Medicine Therapeutics</i> , <b>2009</b> , 1, CMT.S1153		1
40	HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , <b>2009</b> , 35, 121-36	14.4	94
39	Contemporary issues and the potential uses of capecitabine in metastatic breast cancer. <i>Cancer Treatment Reviews</i> , <b>2009</b> , 35, 582-9	14.4	10
38	Breast Cancer in the Post-Genomic Era. <b>2009</b> ,		3
37	Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2009</b> , 32, 369-74	2.7	15
36	Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies. <i>Oncology Reviews</i> , <b>2010</b> , 4, 61-69	4.3	2
35	Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines. <i>Clinical Breast Cancer</i> , <b>2010</b> , 10 Suppl 2, S7-19	3	6

34	Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. <i>BMC Cancer</i> , <b>2010</b> , 10, 28	4.8	13
33	An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. <i>Annals of Oncology</i> , <b>2010</b> , 21, 275-282	10.3	90
32	The cardiac safety of trastuzumab in the treatment of breast cancer. <i>Expert Opinion on Drug Safety</i> , <b>2010</b> , 9, 335-46	4.1	52
31	Current neoadjuvant treatment options for HER2-positive breast cancer. <i>Biologics: Targets and Therapy</i> , <b>2011</b> , 5, 87-94	4.4	9
30	Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. <i>Journal of Breast Cancer</i> , <b>2011</b> , 14, 140-6	3	8
29	Cancer du sein mÈa-analyse en premiÈre ligne. <i>Oncologie</i> , <b>2011</b> , 13, 758-777	1	1
28	A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 603-608	10.3	20
27	Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer. <i>Journal of Chemotherapy</i> , <b>2011</b> , 23, 32-5	2.3	4
26	Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 251-3	2.2	9
25	Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. <i>Annals of Oncology</i> , <b>2012</b> , 23, 3007-3016	10.3	63
24	Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 673-7	8.7	10
23	Cancer du sein. <b>2012</b> ,		
22	The role of targeted therapy and biomarkers in breast cancer treatment. <i>Clinical and Experimental Metastasis</i> , <b>2012</b> , 29, 807-19	4.7	30
21	Treatment of HER2-positive breast cancer: current status and future perspectives. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 9, 16-32	19.4	606
20	Antibodies for Nuclear Medicine Therapy. <i>Medical Radiology</i> , <b>2012</b> , 125-138	0.2	
19	Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial. <i>Breast</i> , <b>2013</b> , 22, 628-33	3.6	7
18	The trastuzumab and vinorelbine combination: an alternative to taxane-based chemotherapy for early-stage and locally advanced her2-positive breast cancer. <i>Current Oncology</i> , <b>2014</b> , 21, e723-7	2.8	4
17	Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2014</b> , 10, 368-75	1.9	5

16	Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 1192-8	14.4	40
15	Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 126	8.3	44
14	Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. <i>Therapeutic Advances in Medical Oncology</i> , <b>2016</b> , 8, 339-50	5.4	23
13	Metastatic and triple-negative breast cancer: challenges and treatment options. <i>Drug Delivery and Translational Research</i> , <b>2018</b> , 8, 1483-1507	6.2	199
12	HER2-Positive Breast Cancer. <b>2019</b> , 63-74		1
11	Monoclonal antibody therapy. <b>2009</b> , 303-406		3
10	Integration of Target-Based Agents in Current Protocols of Breast Cancer Therapy. <b>2009</b> , 203-224		
9	Biological therapy of breast cancer. <b>2009</b> , 669-678		
8	HER2-Targeted Therapy. <b>2010</b> , 373-389		
7	Anti-HER-2 et hormonothérapies dans la prise en charge des cancers du sein: Indications. <b>2012</b> , 553-564		
6	Inflammatory Breast Cancer: Chemotherapy of Metastatic Disease. <b>2012</b> , 101-120		
5	Veille bibliographique cancer du sein méta-analyse en première ligne. Mise à jour des traitements en première ligne métastatique. <b>2012</b> , 77-102		
4	HER2-Targeted Therapy. <b>2016</b> , 391-410		
3	Prise en charge des cancers du sein métastatique HER2 surexprimé <b>2007</b> , 239-252		
2	No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	1
1	Chemotherapeutic Protocols for the Treatment of Breast Cancer. <b>2022</b> , 79-123		0